Hepatic Exosomes

Overview

Parent Cell: Akira Hepatic Stem Cells differentiated from UCT-WJ-MSCs | Hepatocyte-regulatory growth factors and miRNAs for liver repair and regeneration

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Hepatic Exosome Matrix is derived from hepatic stem cells (HSCs) produced by a multi-stage directed differentiation protocol: definitive endoderm (Activin-A/Wnt3a) → hepatic specification (FGF-4/BMP-4) → hepatocyte maturation (Oncostatin-M/HGF/dexamethasone). The resulting hepatocyte-like cells express HNF4α, albumin (ALB), CYP3A4, and ASGR1 — key markers of mature hepatocyte identity — confirming lineage fidelity prior to exosome harvest.

miR-122 is the liver-specific miRNA expressed at high levels almost exclusively in hepatocytes, accounting for approximately 70% of total hepatic miRNA. Its presence in the Hepatic Exosome Matrix cargo is a direct confirmation of liver lineage identity and provides the unique hepatocyte-regulatory functions of this miRNA — including lipid metabolism regulation, viral hepatitis suppression, and hepatocyte differentiation maintenance — in exosome-delivered form.^[1]

Mechanism of Action

Hepatocyte Regeneration (HGF Pathway): HGF is the master hepatic regeneration factor, activating c-Met on hepatocytes to drive proliferation during liver regeneration — the same pathway activated during natural liver regeneration following hepatectomy. EGF provides complementary mitogenic support. Together these growth factors drive hepatocyte re-entry into the cell cycle, critical in acute liver failure and the regenerative phase of chronic liver disease.

Hepatic Fibrosis Resolution: Hepatic stellate cell (HSC) activation to myofibroblasts is the central driver of liver fibrosis in chronic liver disease. HGF and TGF-β3 antagonize TGF-β1-mediated stellate cell activation. miR-let7 suppresses TGF-β pathway components in activated stellate cells. IL-6 from the hepatic secretome paradoxically provides hepatoprotective STAT3 signaling in hepatocytes while suppressing stellate cell fibrogenic activity. These combined anti-fibrotic mechanisms are relevant to NASH, alcoholic liver disease, and viral hepatitis-associated fibrosis.

Liver Inflammation & Immune Modulation: miR-146a suppresses Kupffer cell NF-κB activation, reducing the hepatic macrophage-driven inflammatory cascade in drug-induced liver injury, viral hepatitis, and NASH. IL-10 from the secretome promotes Kupffer cell M2 polarization. miR-21 suppresses PDCD4 in hepatocytes, protecting against TNF-α-induced apoptosis. This hepatic anti-inflammatory program addresses the chronic necro-inflammation driving fibrosis progression.

Lipid Metabolism & NASH: miR-122 regulates hepatic lipid metabolism by modulating fatty acid synthesis (FASN) and cholesterol biosynthesis pathways. Loss of miR-122 in NASH is associated with progressive steatohepatitis and fibrosis. Exosome-delivered miR-122 restoration addresses this miRNA deficit in the NASH liver, potentially reducing steatosis and inflammatory lipotoxicity. HNF4α-associated cargo maintains hepatocyte metabolic identity and lipid handling function.^[2]

Key Molecular Cargo

Therapeutic Applications

???

Clinical & Preclinical Evidence

???